Clinical Trials Logo

Stage IIB Prostate Cancer clinical trials

View clinical trials related to Stage IIB Prostate Cancer.

Filter by:

NCT ID: NCT02237612 Completed - Clinical trials for Adenocarcinoma of the Prostate

Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer

Start date: January 2009
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well diffusion-weighted magnetic resonance imaging (MRI) works in staging patients with prostate cancer that has not spread to nearby lymph nodes or other parts of the body. New imaging techniques, such as diffusion-weighted MRI, may be a less invasive way of predicting the stage and grade of prostate cancer.

NCT ID: NCT02217709 Completed - Clinical trials for Adenocarcinoma of the Prostate

Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

Start date: September 8, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies phenelzine sulfate in treating patients with prostate cancer that has not spread to other parts of the body and has come back. Phenelzine sulfate is a type of antidepressant that works by decreasing the amount of a protein called monoamine oxidase (MAO). MAO drugs may have an anticancer effect in prostate cancer.

NCT ID: NCT02179762 Withdrawn - Clinical trials for Recurrent Prostate Cancer

Vigorous or Moderate Exercise in Enhancing Active Surveillance in Patients With Localized Prostate Cancer

EASE
Start date: August 9, 2014
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial compares vigorous or moderate exercise in enhancing active surveillance in patients with prostate cancer that has not spread to nearby lymph nodes or to other parts of the body. Active surveillance involves watching the patient's condition but not giving any treatment unless test results show that the patient's condition is getting worse. Exercise may improve fitness, quality of life, brain health, and blood biomarkers in patients with prostate cancer on active surveillance. It is not yet known whether vigorous or moderate exercise works better in enhancing active surveillance in patients with localized prostate cancer.

NCT ID: NCT02176902 Active, not recruiting - Clinical trials for Adenocarcinoma of the Prostate

Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer

Start date: November 1, 2014
Phase: N/A
Study type: Interventional

This randomized phase II trial will evaluate if a low omega-6, high omega-3 fat diet combined with fish oil has the potential to delay disease progression in patients with prostate cancer undergoing active surveillance.

NCT ID: NCT02163317 Completed - Clinical trials for Adenocarcinoma of the Prostate

Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

Start date: February 16, 2016
Phase: N/A
Study type: Interventional

This pilot clinical trial studies magnetic resonance (MRI)-guided focal stereotactic radiosurgery (SRS) in treating patients with low- or intermediate-risk localized prostate cancer. Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

NCT ID: NCT02144649 Completed - Clinical trials for Stage IV Prostate Cancer

Tangerine or Red Tomato Juice in Treating Patients With Prostate Cancer Undergoing Surgery

Start date: June 2015
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial compares tangerine and red tomato juice in treating patients with prostate cancer undergoing surgery. A diet high in lycopene, a substance found in tomatoes, may help prevent normal cells from transforming into cancer cells in patients with prostate cancer.

NCT ID: NCT02119858 Completed - Clinical trials for Stage IIB Prostate Cancer

Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery

Start date: July 25, 2014
Phase: Phase 1
Study type: Interventional

This clinical trial studies diffuse optical imaging with indocyanine green solution in imaging pelvic lymph nodes in patients with stage II prostate cancer undergoing surgery. Indocyanine green solution is a special dye that can help doctors see the lymph nodes and blood vessels during surgery when visualized under diffuse optical imaging. Indocyanine green solution may improve the ability to detect lymph nodes and may lead to improved accuracy of lymph node removal.

NCT ID: NCT02048150 Completed - Clinical trials for Adenocarcinoma of the Prostate

Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer

Start date: March 5, 2015
Phase: Phase 1
Study type: Interventional

This pilot clinical trial studies the best dose of anti-prostate specific membrane antigen (PSMA) monoclonal antibody MDX1201-A488 (MDX1201-A488) given before surgery to aid in visualization of the prostate. Attaching a fluorescence, a substance that emits radiation that is visible, to the anti-PMSA antibody and injecting it into the body may help identify the tumor when specialized microscopes are used.

NCT ID: NCT02023463 Active, not recruiting - Clinical trials for Adenocarcinoma of the Prostate

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Start date: April 2, 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best way to give enzalutamide, radiation therapy, and hormone therapy in treating patients with intermediate or high-risk prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x rays to kill tumor cells. Giving enzalutamide, radiation therapy, and hormone therapy may be an effective treatment for prostate cancer.

NCT ID: NCT01992016 Completed - Bone Metastases Clinical Trials

A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine

Start date: April 7, 2014
Phase: N/A
Study type: Interventional

This pilot clinical trial studies fludeoxyglucose F18 (FDG)-positron emission tomography (PET) in imaging patients with prostate cancer treated with ranolazine. Diagnostic procedures, such as FDG-PET, may help find prostate cancer and find out how far the disease has spread. Giving ranolazine may enhance FDG-PET imaging by increasing the amount of glucose available for uptake by the scan.